She said the C.D.C. had spoken to health care providers for young women, including the American College of Obstetricians and Gynecologists. The hiatus and investigation into the rare disorder, she added, should give the public confidence in the vaccine safety monitoring system.
Almost 8 million doses of the Johnson & Johnson vaccine have now been given. There was less than one case per million doses in men and women aged 50 and over.
About 10 million doses or more of the Johnson & Johnson vaccine, which is manufactured at the company's facility in the Netherlands, are on shelves in the United States and could be used immediately. Several states, including Texas, Alabama, Utah, and Wisconsin, said they expected to follow the recommendations of the C.D.C. and F.D.A. once the decision has been made.
Dr. Walensky said she had heard from the governors a keen interest in resuming the use of the shot.
"They were wondering why we were on pause and they were eager to have this back, to have an opportunity for a single dose vaccine, for a once in a lifetime opportunity," she said.
The vaccine has immense potential benefits. If vaccinations are restarted for all adults, 26 to 45 cases of the coagulation disorder are expected in the next six months, according to a model developed by Dr. Sara Oliver, C.D.C. Scientists presented at the meeting on Friday. However, 600 to 1,400 fewer Covid-19-related deaths would be expected over the same period.
The vaccine, which is easy to store and only requires one shot, is also particularly suitable for hard-to-reach populations, including people living in their home country, homeless, or incarcerated.
Other potential cases of the coagulation disorder, including some in men, are currently being investigated. Dr. Shimabukuro also mentioned a case that occurred in a 25-year-old man who was taking part in a clinical trial of the vaccine.